Selected article for: "human include and SARS virus"
Author: Gasparyan, Armen Yuri; Misra, Durga Prasanna; Yessirkepov, Marlen; Zimba, Olena
Title: Perspectives of Immune Therapy in Coronavirus Disease 2019
  • Cord-id: dtzc15up
  • Document date: 2020_5_7
    • ID: dtzc15up
    Snippet: The global fight against coronavirus disease 2019 (COVID-19) is largely based on strategies to boost immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent its severe course and complications. The human defence may include antibodies which interact with SARS-CoV-2 and neutralize its aggressive actions on multiple organ systems. Protective cross-reactivity of antibodies against measles and other known viral infections has been postulated, primarily as a resul
    Document: The global fight against coronavirus disease 2019 (COVID-19) is largely based on strategies to boost immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and prevent its severe course and complications. The human defence may include antibodies which interact with SARS-CoV-2 and neutralize its aggressive actions on multiple organ systems. Protective cross-reactivity of antibodies against measles and other known viral infections has been postulated, primarily as a result of the initial observations of asymptomatic and mild COVID-19 in children. Uncontrolled case series have demonstrated virus-neutralizing effect of convalescent plasma, supporting its efficiency at early stages of contracting SARS-CoV-2. Given the variability of the virus structure, the utility of convalescent plasma is limited to the geographic area of its preparation, and for a short period of time. Intravenous immunoglobulin may also be protective in view of its nonspecific antiviral and immunomodulatory effects. Finally, human monoclonal antibodies may interact with some SARS-CoV-2 proteins, inhibiting the virus-receptor interaction and prevent tissue injury. The improved understanding of the host antiviral responses may help develop safe and effective immunotherapeutic strategies against COVID-19 in the foreseeable future.

    Search related documents:
    Co phrase search for related documents
    • acute lung injury and lopinavir ritonavir: 1, 2, 3, 4, 5
    • acute lung injury and lopinavir ritonavir antiviral: 1
    • acute lung injury and low mortality: 1, 2, 3, 4, 5
    • acute lung injury and lung inflammatory cell infiltration: 1, 2, 3, 4, 5, 6, 7, 8
    • acute lung injury and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute lung injury and lung involvement: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • lopinavir ritonavir and low lymphocyte count: 1, 2
    • lopinavir ritonavir and low mortality: 1, 2, 3, 4, 5, 6, 7, 8
    • lopinavir ritonavir and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • lopinavir ritonavir and lung involvement: 1, 2, 3, 4, 5
    • lopinavir ritonavir antiviral and lung injury: 1, 2, 3, 4
    • lopinavir ritonavir antiviral and lung involvement: 1
    • low lymphocyte count and lung injury: 1
    • low lymphocyte count and lung involvement: 1, 2
    • low mortality and lung injury: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • low mortality and lung involvement: 1, 2, 3, 4